Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP/14 plus HAART in HIV-associated diffuse large B-cell lymphoma
2006-003750-23Phase 4Active
- Sponsor
- Fundación PETHEMA
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in diffuse large B-cell lymphoma (DLBCL) and human immunodeficiency virus infection (HIV), sponsored by Fundación PETHEMA. Primary endpoint: Applicability of R-CHOP/14 plus HAART. Started Mar 2012; status: active.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2006-003750-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003750-23.